The influence of gender, race, and marital status on survival in lung cancer patients: Analysis of radiation therapy oncology group trials

Journal of Thoracic Oncology

Volumn 5, Issue 5, 2010, Pages 631-639

  Siddiqui, Farzan ^a   Bae, Kyounghwa ^b   Langer, Corey J ^c   Coyne, James C ^c   Gamerman, Victoria ^c   Komaki, Ritsuko ^c   Choy, Hak ^d   Curran, Walter J ^e   Watkins Bruner, Deborah ^f   Movsas, Benjamin ^a  

^a HENRY FORD HEALTH SYSTEM   (United States)

^b RTOG   (United States)

^c UNIVERSITY OF PENNSYLVANIA   (United States)

^d UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^e UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^f EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Non small cell lung cancer; Sociodemographic factors; Survival

Indexed keywords

ANTINEOPLASTIC AGENT;

ADULT; AGED; ARTICLE; CANCER PATIENT; CANCER SURVIVAL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; EDUCATIONAL STATUS; FEMALE; GROUPS BY AGE; HISTOLOGY; HUMAN; KARNOFSKY PERFORMANCE STATUS; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; MARRIAGE; MORTALITY; PREDICTION; PRIORITY JOURNAL; PROSPECTIVE STUDY; RACE DIFFERENCE; SEX DIFFERENCE; TUMOR LOCALIZATION; WEIGHT REDUCTION;

EID: 77951860733     PISSN: 15560864     EISSN: 15561380     Source Type: Journal    
DOI: 10.1097/JTO.0b013e3181d5e46a     Document Type: Article

References (59)

1. Parkin DM, Bray F, Ferlay J, et al. Global cancer statistics, 2002. CA Cancer J Clin 2005;55:74-108.
2. Jemal A, Siegel R, Ward E, et al. Cancer statistics, 2008. CA Cancer J Clin 2008;58:71-96.
3. Baldini EH, Strauss GM. Women and lung cancer: waiting to exhale. Chest 1997;112:229S-234S.
4. Belani CP, Marts S, Schiller J, et al. Women and lung cancer: epidemiology, tumor biology, and emerging trends in clinical research. Lung Cancer 2007;55:15-23.
5. Jemal A, Travis WD, Tarone RE, et al. Lung cancer rates convergence in young men and women in the United States: analysis by birth cohort and histologic type. Int J Cancer 2003;105:101-107.
6. CDC. Smoking prevalence among women of reproductive age-United States, 2006. MMWR Weekly 2008;57:849-852.
7. Stanley KE. Prognostic factors for survival in patients with inoperable lung cancer. J Natl Cancer Inst 1980;65:25-32.
8. Sculier JP, Chansky K, Crowley JJ, et al; International Staging Committee and Participating Institutions. The impact of additional prognostic factors on survival and their relationship with the anatomical extent of disease expressed by the 6th Edition of the TNM Classification of Malignant Tumors and the proposals for the 7th Edition. J Thorac Oncol 2008;3:457-466.
9. Konski AA, Pajak TF, Movsas B, et al; Radiation Therapy Oncology Group. Disadvantage of men living alone participating in Radiation Therapy Oncology Group head and neck trials. J Clin Oncol 2006;24: 4177-4183.
10. Smith CT, Williamson PR, Marson AG. Investigating heterogeneity in an individual patient data meta-analysis of time to event outcomes. Stat Med 2005;24:1307-1319.
11. Collett D. Modelling Survival Data in Medical Research, 1st Ed. London: Chapman & Hall; 1994.
12. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958;53:457-481.
13. Cox DR. Regression models and life tables. J R Stat Soc 1972;34:187-202.
14. Albain KS, Crowley JJ, LeBlanc M, et al. Survival determinants in extensive-stage non-small-cell lung cancer: the Southwest Oncology Group experience. J Clin Oncol 1991;9:1618-1626.
15. Cerfolio RJ, Bryant AS, Scott E, et al. Women with pathologic stage I, II, and III non-small cell lung cancer have better survival than men. Chest 2006;130:1796-1802.
16. Chatkin JM, Abreu CM, Fritscher CC, et al. Is there a gender difference in non-small cell lung cancer survival? Gend Med 2004;1:41-47.
17. Ferguson MK, Skosey C, Hoffman PC, et al. Sex-associated differences in presentation and survival in patients with lung cancer. J Clin Oncol 1990;8:1402-1407.
18. O'Connell JP, Kris MG, Gralla RJ, et al. Frequency and prognostic importance of pretreatment clinical characteristics in patients with advanced non-small-cell lung cancer treated with combination chemotherapy. J Clin Oncol 1986;4:1604-1614.
19. Paesmans M, Sculier JP, Libert P, et al. Prognostic factors for survival in advanced non-small-cell lung cancer: univariate and multivariate analyses including recursive partitioning and amalgamation algorithms in 1,052 patients. The European Lung Cancer Working Party. J Clin Oncol 1995;13:1221-1230.
20. Radzikowska E, Glaz P, Roszkowski K. Lung cancer in women: age, smoking, histology, performance status, stage, initial treatment and survival. Population-based study of 20 561 cases. Ann Oncol 2002;13: 1087-1093.
21. Visbal AL, Williams BA, Nichols FC III, et al. Gender differences in non-small-cell lung cancer survival: an analysis of 4,618 patients diagnosed between 1997 and 2002. Ann Thorac Surg 2004;78:209 -215; discussion 215.
22. Wakelee HA, Wang W, Schiller JH, et al; for the Eastern Cooperative Oncology Group. Survival differences by sex for patients with advanced non-small cell lung cancer on Eastern Cooperative Oncology Group trial 1594. J Thorac Oncol 2006;1:441-446.
23. Werner-Wasik M, Scott C, Cox JD, et al. Recursive partitioning analysis of 1999 Radiation Therapy Oncology Group (RTOG) patients with locally-advanced non-small-cell lung cancer (LA-NSCLC): identification of five groups with different survival. Int J Radiat Oncol Biol Phys 2000;48:1475-1482.
24. Belani C, von Pawel J, Pluzanska A, et al. Phase III study of docetaxelcisplatin (DC) or docetaxel-carboplatin (DCb) versus vinorelbine-cisplatin (VC) as first-line treatment of advanced non-small cell lung cancer (NSCLC): analyses by gender (abstract). Lung Cancer 2005;49:S235-S236.
25. Caldarella A, Crocetti E, Comin CE, et al. Gender differences in non-small cell lung cancer: a population-based study. Eur J Surg Oncol 2007;33:763-768.
26. Foegle J, Hedelin G, Lebitasy MP, et al. Specific features of non-small cell lung cancer in women: a retrospective study of 1738 cases diagnosed in Bas-Rhin between 1982 and 1997. J Thorac Oncol 2007;2: 466-474.
27. Mandrekar SJ, Northfelt DW, Schild SE, et al. Impact of pretreatment factors on adverse events: a pooled analysis of North Central Cancer Treatment Group advanced stage non-small cell lung cancer trials. J Thorac Oncol 2006;1:556-563.
28. Yamamoto H, Sekine I, Yamada K, et al. Gender differences in treatment outcomes among patients with non-small cell lung cancer given a combination of carboplatin and paclitaxel. Oncology 2008;75:169-174.
29. Robnett TJ, Machtay M, Vines EF, et al. Factors predicting severe radiation pneumonitis in patients receiving definitive chemoradiation for lung cancer. Int J Radiat Oncol Biol Phys 2000;48:89-94.
30. Lynch TJ, Bell DW, Sordella R, et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of nonsmall- cell lung cancer to gefitinib. N Engl J Med 2004;350:2129-2139.
31. Hsieh RK, Lim KH, Kuo HT, et al. Female sex and bronchioloalveolar pathologic subtype predict EGFR mutations in non-small cell lung cancer. Chest 2005;128:317-321.
32. Wu CT, Chang YL, Shih JY, et al. The significance of estrogen receptor beta in 301 surgically treated non-small cell lung cancers. J Thorac Cardiovasc Surg 2005;130:979-986.
33. Davis M. Gender differences in p-glycoprotein: drug toxicity and response. J Clin Oncol 2005;23:6439-6440.
34. Lord RV, Brabender J, Gandara D, et al. Low ERCC1 expression correlates with prolonged survival after cisplatin plus gemcitabine chemotherapy in non-small cell lung cancer. Clin Cancer Res 2002;8:2286-2291.
35. Henschke CI, Yip R, Miettinen OS. Women's susceptibility to tobacco carcinogens and survival after diagnosis of lung cancer. JAMA 2006; 296:180-184.
36. Bunone G, Briand PA, Miksicek RJ, et al. Activation of the unliganded estrogen receptor by EGF involves the MAP kinase pathway and direct phosphorylation. EMBO J 1996;15:2174-2183.
37. Levin ER. Integration of the extranuclear and nuclear actions of estrogen. Mol Endocrinol 2005;19:1951-1959.
38. Pietras RJ, Marquez DC, Chen HW, et al. Estrogen and growth factor receptor interactions in human breast and non-small cell lung cancer cells. Steroids 2005;70:372-381.
39. Razandi M, Pedram A, Park ST, et al. Proximal events in signaling by plasma membrane estrogen receptors. J Biol Chem 2003;278:2701-2712.
40. Stabile LP, Lyker JS, Gubish CT, et al. Combined targeting of the estrogen receptor and the epidermal growth factor receptor in non-small cell lung cancer shows enhanced antiproliferative effects. Cancer Res 2005;65:1459-1470.
41. Hershberger PA, Vasquez AC, Kanterewicz B, et al. Regulation of endogenous gene expression in human non-small cell lung cancer cells by estrogen receptor ligands. Cancer Res 2005;65:1598-1605.
42. Ganti AK, Sahmoun AE, Panwalkar AW, et al. Hormone replacement therapy is associated with decreased survival in women with lung cancer. J Clin Oncol 2006;24:59-63.
43. Taioli E, Wynder EL. Re: Endocrine factors and adenocarcinoma of the lung in women. J Natl Cancer Inst 1994;86:869-870.
44. Ryberg D, Hewer A, Phillips DH, et al. Different susceptibility to smoking-induced DNA damage among male and female lung cancer patients. Cancer Res 1994;54:5801-5803.
45. Wei Q, Cheng L, Amos CI, et al. Repair of tobacco carcinogen-induced DNA adducts and lung cancer risk: a molecular epidemiologic study. J Natl Cancer Inst 2000;92:1764-1772.
46. Mollerup S, Berge G, Baera R, et al. Sex differences in risk of lung cancer: expression of genes in the PAH bioactivation pathway in relation to smoking and bulky DNA adducts. Int J Cancer 2006;119:741-744.
47. Dresler CM, Fratelli C, Babb J, et al. Gender differences in genetic susceptibility for lung cancer. Lung Cancer 2000;30:153-160.
48. Alexandrov K, Cascorbi I, Rojas M, et al. CYP1A1 and GSTM1 genotypes affect benzo[a]pyrene DNA adducts in smokers' lung: comparison with aromatic/hydrophobic adduct formation. Carcinogenesis 2002;23:1969 -1977.
49. Nelson HH, Christiani DC, Mark EJ, et al. Implications and prognostic value of K-ras mutation for early-stage lung cancer in women. J Natl Cancer Inst 1999;91:2032-2038.
50. Guinee DG Jr, Travis WD, Trivers GE, et al. Gender comparisons in human lung cancer: analysis of p53 mutations, anti-p53 serum antibodies and C-erbB-2 expression. Carcinogenesis 1995;16:993-1002.
51. Hainaut P, Pfeifer GP. Patterns of p53 G3T transversions in lung cancers reflect the primary mutagenic signature of DNA-damage by tobacco smoke. Carcinogenesis 2001;22:367-374.
52. Kure EH, Ryberg D, Hewer A, et al. p53 mutations in lung tumours: relationship to gender and lung DNA adduct levels. Carcinogenesis 1996;17:2201-2205.
53. Toyooka S, Tsuda T, Gazdar AF. The TP53 gene, tobacco exposure, and lung cancer. Hum Mutat 2003;21:229-239.
54. Mittelstrass K, Sauter W, Rosenberger A, et al. Early onset lung cancer, cigarette smoking and the SNP309 of the murine double minute-2 (MDM2) gene. BMC Cancer 2008;8:113.
55. Lai H, Lai S, Krongrad A, et al. The effect of marital status on survival in late-stage cancer patients: an analysis based on surveillance, epidemiology, and end results (SEER) data, in the United States. Int J Behav Med 1999;6:150-176.
56. Kravdal O. The impact of marital status on cancer survival. Soc Sci Med 2001;52:357-368.
57. Kvikstad A, Vatten LJ, Tretli S. Widowhood and divorce in relation to overall survival among middle-aged Norwegian women with cancer. Br J Cancer 1995;71:1343-1347.
58. Jatoi A, Novotny P, Cassivi S, et al. Does marital status impact survival and quality of life in patients with non-small cell lung cancer? Observations from the mayo clinic lung cancer cohort. Oncologist 2007;12: 1456-1463.
59. Saito-Nakaya K, Nakaya N, Akechi T, et al. Marital status and non-small cell lung cancer survival: the Lung Cancer Database Project in Japan. Psychooncology 2008;17:869-876.